Latest News:- Erythropoietin Stimulating Agents Market: Epoetin alfa is expected to lead the Type segment during 2024-2028

Erythropoietin Stimulating Agents Market to grow at a CAGR of 8.5% during 2024-2028

The Erythropoietin Stimulating Agents Market is expected to grow at a CAGR of 8.5% during 2023 and 2028. During this period, the market is also expected to show a growth of USD 4505.4 million. In the global erythropoietin stimulating agents (ESA) market, developing economies, including China, India, and Brazil, are experiencing a significant rise in the prevalence of Chronic Kidney Disease (CKD), leading to increased demand for ESAs. This trend is motivating ESA vendors to invest in these markets, as evidenced by Asia Dialysis Network, NephroPlus, which announced a USD25 million investment in India to capitalize on growth opportunities in the Asia-Pacific region. Additionally, Renal Project, a healthcare startup in India, secured USD0.3 million in funding from angel investors to expand its dialysis micro centers. The proliferation of dialysis centers in developing countries, such as Brazil, is expected to generate new business prospects for ESAs market participants. 

Get more information on Erythropoietin Stimulating Agents Market by requesting a sample report

The Epoetin alfa subsegment is expected to dominate the Type segment during the forecast period 

Technavio analysts predict that the Epoetin alfa subsegment will lead the Type segment during 2024 and 2028 Epoetin alfa, a leading sub-segment in the Erythropoietin Stimulating Agents (ESA) market, is widely utilized for addressing anemia in chronic kidney disease (CKD) patients and serving as an anti-coagulant to mitigate the risk of severe blood clots. These medications also minimize the requirement for blood transfusions prior to surgeries with a significant risk of blood loss. Epoetin alfa drugs have gained popularity due to their simpler mechanism compared to natural Erythropoietin (EPO), which signals the bone marrow to augment the production of red blood cells (RBCs). Additionally, they find application in the treatment of various conditions, such as human immunodeficiency virus (HIV) and cancer.

Here are the various ways based on which the market is segmented: 

• Type
  • Epoetin alfa
  • Epoetin beta
  • Darbepoetin alfa
  • Others
• Geography
  • North America
  • Europe
  • Asia
  • Rest of World (ROW)

Reasons to Purchase the Global Erythropoietin Stimulating Agents Market Market Research Report by Technavio. What is in it for you?

• Wealth of Experience: Technavio is an established name in the world of market research. It holds an expertise of more than 20 years in the field, has published 21,000+ reports thereby extensively covering the area in various industries and range of regions
• Insight into Current Market Trends: Our research reports provide our readers insights into the latest market intelligence, competitor strategies, market trends, changes taking place in the industry and customer preferences, forecasted market opportunities that influence them to make better business decisions
• High ROI with Extensive Hands-on Research: Technavio is renowned for offering personalized market research reports as per unique business needs, delving deep into specific markets, product segments and demographics. Additionally, it is also well-known for providing high return on investments through its wide collection of data at pocket-friendly rates

There are several factors that are causing the market to flourish presence of large pool of ckd patients

Learn which are the obstacles that the market is experiencing in the way of its growth by accessing the free PDF report

Research Analysis Overview

The Erythropoietin Stimulating Agents (ESAs) market encompasses various therapeutic agents, with Darbepoetin being a notable member. ESAs find extensive application in managing anemia, particularly in patients with chronic kidney disease undergoing dialysis, motor performance enhancement in patients with brain injury, and neuroprotection in conditions like hypoxic-ischemic encephalopathy. Motor performance improvement and neuroprotection are crucial in stroke patients, traumatic brain injuries, and premature infants. ESAs, including Erythropoietin, are increasingly being used in critical care units and emergency departments due to the rising number of trauma cases, road traffic injuries, and perioperative hypothermia. The healthcare spending on ESAs is escalating due to the growing geriatric and infant populations, chronic diseases, and surgical procedures. Neurogenesis, a potential therapeutic application, is under exploration for its role in brain injury and neuroprotection. Intravenous Warming Systems and body warmers are often used in conjunction with ESAs to maintain optimal body temperature during surgeries and other medical procedures. Respiratory physiology is another area of interest, as ESAs may help improve oxygenation and reduce the need for mechanical ventilation. Overall, the ESA market is poised for significant growth, driven by the increasing demand for effective treatment options in various clinical applications.

Market Research Overview

The global pharmaceuticals market encompasses entities involved in the research and development (R&D) or production of various offerings, including generic drugs, non-generic drugs, and veterinary drugs. According to Technavio, the healthcare industry's total revenue is determined by the earnings generated by manufacturers and providers of medical equipment, supplies, pharmaceuticals, biotechnology, and life sciences tools and services. Factors propelling the expansion of the pharmaceuticals market include the increasing elderly population. By 2050, approximately one-quarter of the US population is projected to be over 60 years old, while Europe is anticipated to reach a similar demographic ratio by 2030. This demographic shift is expected to fuel demand for healthcare solutions, including pharmaceuticals, as the elderly population typically requires more medical attention.

The Erythropoietin Stimulating Agents Market is experiencing significant growth, fueled by the presence of large pool of ckd patients. Industries are leveraging the products belonging to the market for customer engagement, transactional notifications, and promotional offers.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/